Literature DB >> 26811711

Applying low-intensity pulsed ultrasounds (LIPUS) to a zoledronate-associated atypical femoral shaft fracture without cessation of zoledronate therapy for 3 years follow up: a case report.

Shoutaro Arakawa1, Mitsuru Saito1, Makoto Kubota1, Hidehiko Suzuki1, Shigeki Tsuchida1, Kurando Hashimoto1, Keishi Marumo1.   

Abstract

Reports are increasing regarding atypical femoral fractures (AFFs) caused by minor trauma in patients using bisphosphonates (BPs) for long periods. Patients with malignant skeletal metastases potentially are at greater risk for these AFFs, especially considering the high dose and the duration of treatment with BPs. We evaluated a case of atypical femoral shaft fracture treated with an intramedullary nail in a patient treated for five years with zoledronate who had breast cancer with metastases to bone. Although bone union was achieved without cessation of zoledronate therapy by applying low-intensity pulsed ultrasounds (LIPUS), the remodeling phase of the fracture healing process was delayed. For BPs-associated AFFs, LIPUS is an alternative to parathyroid hormone (PTH) analogs such as teriparatide that are contraindicated in patients with malignant skeletal metastases. LIPUS is an effective treatment for fracture healing and may avoid the necessity to discontinue BP therapy.

Entities:  

Keywords:  LIPUS; atypical femoral fracture; bisphosphonate; breast cancer; malignant skeletal metastasis; zoledronate

Year:  2015        PMID: 26811711      PMCID: PMC4708976          DOI: 10.11138/ccmbm/2015.12.3.269

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  21 in total

1.  Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats.

Authors:  J Li; S Mori; Y Kaji; J Kawanishi; T Akiyama; H Norimatsu
Journal:  J Bone Miner Res       Date:  2000-10       Impact factor: 6.741

2.  Acceleration of tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound.

Authors:  J D Heckman; J P Ryaby; J McCabe; J J Frey; R F Kilcoyne
Journal:  J Bone Joint Surg Am       Date:  1994-01       Impact factor: 5.284

3.  Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.

Authors:  Katerina Cermak; Felix Shumelinsky; Jean Alexiou; Michael J Gebhart
Journal:  Clin Orthop Relat Res       Date:  2009-12-18       Impact factor: 4.176

4.  Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies.

Authors:  N Napoli; D Novack; R Armamento-Villareal
Journal:  Osteoporos Int       Date:  2009-08-11       Impact factor: 4.507

5.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

6.  Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.

Authors:  Stephen J Gomberg; Rosanna L Wustrack; Nicola Napoli; Claude D Arnaud; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2011-03-23       Impact factor: 5.958

7.  Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid.

Authors:  Greg Wernecke; Surena Namdari; Surena Namduri; Edward F DiCarlo; Robert Schneider; Joseph Lane
Journal:  HSS J       Date:  2008-07-16

Review 8.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

Review 9.  Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review.

Authors:  Kazunori Hayashi; Masanari Aono; Kousuke Shintani; Kenichi Kazuki
Journal:  Anticancer Res       Date:  2014-03       Impact factor: 2.480

10.  Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.

Authors:  M Saito; S Mori; T Mashiba; S Komatsubara; K Marumo
Journal:  Osteoporos Int       Date:  2008-03-29       Impact factor: 5.071

View more
  3 in total

1.  High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; T Nakatsue; Y Wada; J Fujisawa; J J Kazama; T Kuroda; Y Suzuki; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2017-04-13       Impact factor: 4.507

Review 2.  Treatment strategy for atypical ulnar fracture due to severely suppressed bone turnover caused by long-term bisphosphonate therapy: a case report and literature review.

Authors:  Kensaku Abe; Hiroaki Kimura; Norio Yamamoto; Shingo Shimozaki; Takashi Higuchi; Yuta Taniguchi; Takaaki Uto; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2020-12-03       Impact factor: 2.362

Review 3.  Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention.

Authors:  Judith Sarah Bubbear
Journal:  Rambam Maimonides Med J       Date:  2016-10-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.